Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Published:2021-01-12 Issue:10 Volume:148 Page:2557-2570
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Daniel Davey¹,Kuchava Vladimer²,Bondarenko Igor³,Ivashchuk Oleksandr⁴,Reddy Sreekanth⁵,Jaal Jana⁶,Kudaba Iveta⁷,Hart Lowell⁸,Matitashvili Amiran⁹,Pritchett Yili¹⁰,Morris Shannon R.¹⁰,Sorrentino Jessica A.¹⁰,Antal Joyce M.¹⁰,Goldschmidt Jerome¹¹

Affiliation:

1. Sarah Cannon Research Institute, Tennessee Oncology‐Chattanooga Chattanooga Tennessee USA

2. LTD Institute of Clinical Oncology Tbilisi Georgia

3. Dnipropetrovsk Medical Academy Dnipro Ukraine

4. Chernivtsi Regional Clinical Oncology Centre Chernivtsi Ukraine

5. Northside Hospital, Inc Atlanta Georgia USA

6. Department of Hematology‐Oncology University of Tartu Tartu Estonia

7. Latvian Oncology Centre Riga East University Hospital Riga Latvia

8. Florida Cancer Specialists Fort Myers Florida USA

9. LTD Cancer Research Centre Tbilisi Georgia

10. G1 Therapeutics Research Triangle Park North Carolina USA

11. Blue Ridge Cancer Care Blacksburg Virginia USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33453

Reference54 articles.

1. Cisplatin plus etoposide in small cell lung cancer;Loehrer PJ;Semin Oncol,1988

2. Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

3. Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

4. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

5. Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03

2. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES);Lung Cancer;2024-02

3. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline;Journal of Clinical Oncology;2023-12-10

4. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy;Advances in Therapy;2023-07-25

5. Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer;Breast Cancer Research and Treatment;2023-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3